Progress in the treatment of IgA nephropathy.docVIP

 PAGE \* MERGEFORMAT 6 Progress in the treatment of IgA nephropathy Author: Li Zhanting Sun Ji-Feng Yang Alex Liu Lili Wang Li [Abstract] IgA nephropathy is the most common primary glomerular diseases, because of its disease mechanisms are not yet clear, is currently no specific treatments. Clinical treatment goal is to effectively reduce proteinuria, control blood pressure and (or) high uric acid and reduce further injury of renal tissue to maintain a stable renal function. For patients with repeated episodes of microscopic hematuria, tonsillectomy as a means of treatment; of isolated hematuria and pathological changes in light, primarily to strengthen follow-up observation; For urine protein and (or) the slow progress in hypertension IgA nephropathy, angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists can be used for the majority of cases, if necessary, can be used with glucocorticoids, cytotoxic drugs can also be applied or mycophenolate mofetil treatment with immunosuppressive agents such as; the high-risk patients with rapid progression that can be used glucocorticoid pulse therapy, or use cytotoxic drugs or immunosuppressive agents such as intensive therapy. [Keywords:] IgA nephropathy treatment 0 Introduction IgA nephropathy (IgA nephropathy, IgAN) is an immune pathology refers to the main IgA or IgA immunoglobulin in the glomerular mesangial areas and capillary loops showed diffuse granular or corporation caused by deposition of a series of massive Clinical and pathological changes [1]. In addition to IgAN, some systemic diseases can also be combined IgA deposition in mesangial area and cause a corresponding clinical symptoms, such as: systemic lupus erythematosus, Henoch-Schonlein purpura and so on. IgAN is common in young adults (20 to 30-year-old high-fat), more men than women, more common, the incidence of different regions are quite different in different clinical manifestations, prognosis, not the same. most common f